XML 74 R66.htm IDEA: XBRL DOCUMENT
v3.24.3

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | ---
Oct. 30, 2023 | Feb. 28, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Jun. 28, 2024 | Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
CVR derivative liability |  |  | $ 4,900 |  |  | $ 4,722
Purchase of property and equipment |  |  | 2,380 | $ 6,193 |  |
Maximum |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Investment obligation amount |  |  |  |  | $ 4,200 |
Percentage of equity interest |  |  |  |  | 18.90% |
Property and Equipment |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Purchase of property and equipment |  |  | 1,600 |  |  |
Research and Development |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Committed to allocate |  |  | $ 21,300 |  |  |
Contingent Value Rights Agreement |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Percentage of excess cash on dispositions net |  |  | 100.00% |  |  |
Excess amount retained from net proceeds related to disposition of assets |  |  | $ 1,000 |  |  |
Percentage of excess preapproved costs |  |  | 100.00% |  |  |
Distribution to CVR holders from asset sale proceeds |  | $ 200 |  |  |  |
Long-term CVR derivative liability |  | $ 4,500 |  |  |  |
CVR derivative liability |  |  |  |  |  | $ 4,700
Contributions closing payable amount | $ 1,100 |  |  |  |  |
Remaining outstanding balance |  |  | $ 0 |  |  |
F351 | Gyre Pharmaceuticals | Submission of the New Drug Application |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | 4,700 |  |  |
F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | 1,200 |  |  |
F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | $ 7,100 |  |  |

X
- Definition CVR derivative liability noncurrent. + References No definition available. + Details
Name: | gyre_CVRDerivativeLiabilityNoncurrent
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments and contingencies disclosure. + References No definition available. + Details
Name: | gyre_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | gyre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Committed to allocate. + References No definition available. + Details
Name: | gyre_CommittedToAllocate
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights derivative liability non current. + References No definition available. + Details
Name: | gyre_ContingentValueRightsDerivativeLiabilityNonCurrent
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contributions closing payable amount. + References No definition available. + Details
Name: | gyre_ContributionsClosingPayableAmount
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Distribution from asset sale proceeds. + References No definition available. + Details
Name: | gyre_DistributionFromAssetSaleProceeds
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Excess amount retained from net proceeds related to disposition of assets. + References No definition available. + Details
Name: | gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investment subscription amount. + References No definition available. + Details
Name: | gyre_InvestmentSubscriptionAmount
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Obligation to pay in exchange for the intellectual property rights. + References No definition available. + Details
Name: | gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of equity interest. + References No definition available. + Details
Name: | gyre_PercentageOfEquityInterest
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of excess cash on dispositions net. + References No definition available. + Details
Name: | gyre_PercentageOfExcessCashOnDispositionsNet
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of excess preapproved costs. + References No definition available. + Details
Name: | gyre_PercentageOfExcessPreapprovedCosts
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining outstanding balance of agreement. + References No definition available. + Details
Name: | gyre_RemainingOutstandingBalanceOfAgreement
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |